https://cangrelorinhibitor.com..../r-cys223tyr-mutatio
Group A received 1.17 ± 0.09 GBq/cycle; team B, 1.89 ± 0.53 GBq/cycle; and group C, 3.97 ± 0.84 GBq/cycle. The treatment was planned for up to 3 rounds. Treatment-related adverse activities were graded in line with the National Cancer Institute Common Terminology Criteria for unpleasant Activities (CTCAE), version 5.0. Treatment response ended up being evaluated according to the European organization for analysis and remedy for Cancer criteria and modified PERCIST. Results Administration of P
Like
Comment
Share
